| Literature DB >> 3520171 |
S Sterioff, D E Engen, H Zincke.
Abstract
During the course of 3 decades, and particularly during the past 5 years, clinical renal transplantation has improved to become a safe mode of therapy for end-stage renal disease. Currently, more than 95% 1-year survival can be expected, both in patients who receive allografts from living-related donors and in those who receive cadaver kidneys. One-year living-related donor graft survival is 98%, and 1-year cadaver graft survival is 87%. Cyclosporine has been an important adjunctive immunosuppressive agent not only because of improved results but also because it has shortened hospitalization time.Entities:
Mesh:
Substances:
Year: 1986 PMID: 3520171 DOI: 10.1016/s0025-6196(12)62007-2
Source DB: PubMed Journal: Mayo Clin Proc ISSN: 0025-6196 Impact factor: 7.616